In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

Akero Therapeutics claimed a win in severe MASH on Monday morning, as the company’s candidate efruxifermin showed a 24% ...

KEY TAKEAWAYS: 70% of Sponsors miss their milestones by an average of eight months, suggesting the clinical trial recruitment ...

A London-based biotech has emerged from stealth with a personalized T cell therapy platform that it says could create ...

Five months after the FDA blocked its plans for accelerated approval, Agenus is moving ahead with discussions with potential ...

Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...

Merck's Keytruda and Eisai's Lenvima combo with chemo failed survival endpoint in gastroesophageal cancer study, but ...

President Donald Trump's communications pause for HHS, FDA and other health-related agencies could push some drug approval ...

Takeda has ended the manufacturing and supply of its gout drug Uloric in the US market as more patients turn to generic ...

Novo Nordisk, Eli Lilly, and others are advancing obesity drugs, with key data expected for assets including CagriSema, ...

Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...